^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    alnuctamab (CC-93269)

    i
    Other names: CC-93269, EM901, EM-901, BMS-986349, BMS986349, CC93269, BMS 986349, CC 93269, EM 901
    Company:
    BMS
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    5d
    Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways. (PubMed, Blood)
    Mezigdomide treatment in exhausted T cells results in decreased expression of exhaustion-related markers, increased proinflammatory cytokine expression, and enhanced target cell killing with Alnuctamab, a B-cell maturation antigen (BCMA) targeting TCE. This study provides crucial mechanistic insights into the roles of IKZF1/IKZF3 in T cell exhaustion, supporting the rationale for combining mezigdomide with TCEs to enhance therapeutic outcomes in MM.
    Journal • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    alnuctamab (CC-93269) • mezigdomide (CC-92480)
    27d
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed
    Enrollment change • Trial termination
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    5ms
    Alnuctamab for Refractory SLE (LATTE Study) (clinicaltrials.gov)
    P1, N=21, Recruiting, Icahn School of Medicine at Mount Sinai | Not yet recruiting --> Recruiting
    Enrollment open
    |
    alnuctamab (CC-93269)
    7ms
    Alnuctamab for Refractory SLE (LATTE Study) (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Icahn School of Medicine at Mount Sinai
    New P1 trial
    |
    alnuctamab (CC-93269)
    1year
    CC-93269-MM-001: Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=183, Terminated, Celgene | Active, not recruiting --> Terminated; Business objectives have changed
    Trial termination • First-in-human
    |
    alnuctamab (CC-93269)
    1year
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=156, Active, not recruiting, Celgene | Trial completion date: Aug 2025 --> May 2025
    Trial completion date
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    1year
    CC-93269-MM-001: Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=250, Active, not recruiting, Celgene | Trial completion date: Aug 2029 --> Mar 2025 | Trial primary completion date: Jun 2029 --> Mar 2025
    Trial completion date • Trial primary completion date • First-in-human
    |
    alnuctamab (CC-93269)
    over1year
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=156, Active, not recruiting, Celgene | Phase classification: P1/2 --> P1 | Trial primary completion date: Aug 2025 --> May 2025
    Phase classification • Trial primary completion date • Combination therapy
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    over1year
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=156, Active, not recruiting, Celgene | Trial completion date: Feb 2032 --> Aug 2025 | Trial primary completion date: Feb 2032 --> Aug 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    almost2years
    ALUMMINATE: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=0, Withdrawn, Celgene | N=466 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • alnuctamab (CC-93269)
    almost2years
    CC-93269-MM-001: Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=250, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    alnuctamab (CC-93269)
    almost2years
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=156, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)